EMEA And APAC Expansion Combined With Rising Retail Demand Will Shape Future Trading

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

06 Aug 24

Updated

13 Dec 25

Views

214

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

13.1%

7D

-1.1%

Loading

1Y

13.1%

7D

-1.1%

You can edit this narrative until Dec 14 2:05 PM. Then, changes will post as Updates.

Author's Valuation

US$286.136.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 13 Dec 25

Fair value Increased 0.36%

CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility

Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.

Shared on 16 Nov 25

Fair value Increased 1.07%

CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead

The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.

Shared on 07 May 25

Fair value Increased 5.01%

Shared on 30 Apr 25

Fair value Decreased 2.61%

AnalystConsensusTarget has decreased revenue growth from 5.6% to 4.7%.

Shared on 23 Apr 25

Fair value Increased 0.87%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to -0.0%.

Shared on 16 Apr 25

Fair value Increased 0.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 2.88%

AnalystConsensusTarget has increased revenue growth from 4.8% to 5.7%.

Shared on 02 Apr 25

Fair value Increased 2.51%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.72%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 8.26%

AnalystConsensusTarget has increased revenue growth from 3.5% to 4.7%.

AnalystConsensusTarget Fair Value

US$286.13

6.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

4.50%

Capital Markets revenue growth rate

0.25%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.16%

Calculation

US$4.00b

Earnings '28

x

32.75x

PE Ratio '28

=

US$130.84b

Market Cap '28

US$130.84b

Market Cap '28

/

361.33m

No. shares '28

=

US$362.12

Share Price '28

US$362.12 Share Price '28

Discounted to 2025 @ 8.20% p.a.

=

US$285.87

Fair Value '25